OTC/SmallCap IRW
Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug
SHELTON, Conn., Sept. 22, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the significant advantages gained by remdesivir encapsulation ...
2021-09-22 18:45
6345
BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone
VANCOUVER, British Columbia, Sept. 17, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that cancer vaccine manufacturing partner Bio Elpida inLyon, France, has reached major milestones in the development of the bioproduction proce...
2021-09-17 15:00
6517
Sasol, Haldor Topsøe expand G2LTM licensing collaboration to grow sustainable synthetic fuels and chemicals globally
JOHANNESBURG, Sept. 15, 2021 /PRNewswire/ -- Haldor Topsøe and Sasol have expanded collaboration to jointly license and develop their technologies for sustainable liquid fuels and chemicals production through Fischer-Tropsch (FT) technology. Sasol and Topsøe currently offer integrated end-to-end...
2021-09-15 20:23
8244
10,000 green hydrogen generators per month: groundbreaking for Enapter electrolyser mass production in North Rhine-Westphalia
Acting, not talking. - Enapter Campus enables mass production of AEM Electrolysers and serves as a blueprint for further Enapter production facilities worldwide - Electrolyser production, warehouse storage and offices, as well as research and development laboratories will be built over 82,000...
2021-09-15 04:25
5362
BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs
VANCOUVER, BC, Sept. 14, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that global CDMO partner WuXi Biologics, has completed the synthesis of recombinant SARS-CoV-2 s-protein for BVX-0320, the company's COVID-19 vaccine candida...
2021-09-14 15:00
6559
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval
The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care Number of U.S. sites for the study has also been expanded RHB-107, a nov...
2021-09-13 19:00
7032
Sasol and Central Energy Fund sign strategic MOU to accelerate gas development in South Africa
JOHANNESBURG, Sept. 7, 2021 /PRNewswire/ -- Sasol and the Central Energy Fund (CEF) have signed a memorandum of understanding (MOU) to collaborate on accelerating the development of gas solutions inSouth Africa. This agreement brings togetherSouth Africa's two leading pioneers of the gas industry...
2021-09-07 20:58
6795
Further Study in humans shows that the DTH response, the basis for CoviDTH, is highly durable and persists for at least one year after COVID-19 exposure or vaccine administration
VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Sept. 7, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that the Scientific Advisor for its CoviDTH program,Yvelise Barrios, MD, PhD, and Clinical Immuno...
2021-09-07 20:00
7196
NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease
-- Using NeuExcell's neuroregenerative gene therapy platform, the collaboration aims to develop an effective and safe treatment for patients suffering from Huntington's Disease. -- Spark Therapeutics' excellence in R&D and proprietary adeno-associated virus (AAV) vector gene therapy platform ma...
2021-09-07 12:00
4507
Fosun International Officially Selected as a Constituent Stock of Hang Seng ESG 50 Index
HONG KONG, Sept. 6, 2021 /PRNewswire/ -- Fosun International officially was selected as a constituent stock of Hang Seng ESG 50 Index (top 50 large-to-mid cap). Hang Seng ESG 50 Index aims at capturing the overall performance of Top 50 ESG leaders with relatively high market capitalization listed...
2021-09-06 16:51
8084
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 315 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 314 media titles]
2026-08-27 10:25
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 309 media titles]
2026-09-02 08:30Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 309 media titles]
2026-09-02 12:17
Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 302 media titles]
2026-09-01 11:00
Most Read
Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
2026-08-27 10:25
18035